Educational Webinars-Standalone Page
This multimedia content is made available for HCPs specializing in oncology for learning and information purposes only to address the need of the medical community to better understand investigational interventions and the physiology of disease
View Educational Webinars from GSK oncology
Multiple Myeloma Conversations Webinar on BCMA-Targeted Therapies in Relapsed Refractory Multiple Myeloma
Learn about ways to maximize efficacy, moderate adverse events, and improve the patient experience when using novel BCMA-targeted therapies in RRMM. This webinar/symposium was originally delivered on November 30, 2021, when BLENREP monotherapy was approved in the US and EU for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US and EU. The GSK compound discussed in this presentation is investigational. The information in this presentation is not intended to imply that clinical safety or efficacy of the compound has been established to the satisfaction of any regulatory authority or that it will receive regulatory approval.
European Hematology Association (EHA) 2023 Symposium on Addressing the Challenges of Anaemia and Thrombocytopenia in Myelofibrosis
Learn more about the significant burden of anemia and thrombocytopenia on patients and the current and emerging treatment options in MF in addition to case presentations followed by an expert panel discussion.
Myeloproliferative Neoplasms Controversies and Debates (MPN Co & D) 2023 Symposium on Raising the Bar in Cytopenic Myelofibrosis
Learn more about the implications and medical needs associated with anaemia and thrombocytopenia in patients with myelofibrosis, and the associated available and emerging agents, in addition to patient case presentations and an expert panel discussion.
Controversies in Multiple Myeloma (COMy) 2023 Symposium on Novel BCMA-based Combination Therapies in Early Relapsed Refractory Multiple Myeloma
Learn more about the changing treatment landscape associated with multiple myeloma, and novel BCMA-based combination regimens in early RRMM. This webinar/symposium was originally delivered on May 11, 2023, when BLENREP monotherapy was approved in the EU for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US and EU. The GSK compound discussed in this presentation is investigational. The information in this presentation is not intended to imply that clinical safety or efficacy of the compound has been established to the satisfaction of any regulatory authority or that it will receive regulatory approval.
European Hematology Association (EHA) 2023 Symposium on Novel BCMA-based Combination Therapies in Early Relapsed Refractory Multiple Myeloma
Learn more about novel BCMA-based combination regimens in early RRMM, and real-world practical approaches to improving the benefit-risk profile with BCMA-targeted agents in earlier lines of therapy. This webinar/symposium was originally delivered on June 8, 2023, when BLENREP monotherapy was approved in the EU for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US and EU. The GSK compound discussed in this presentation is investigational. The information in this presentation is not intended to imply that clinical safety or efficacy of the compound has been established to the satisfaction of any regulatory authority or that it will receive regulatory approval.
Multiple Myeloma Conversations Webinar on Real World Evidence for the use of BCMA-Targeted Therapies in Relapsed Refractory Multiple Myeloma
Learn more about emerging real-world evidence data for BCMA-targeted agents and practical considerations for selection of BCMA-targeted therapies in RRMM. This webinar/symposium was originally delivered on April 24, 2023, when BLENREP monotherapy was approved in the EU for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US and EU. The GSK compound discussed in this presentation is investigational. The information in this presentation is not intended to imply that clinical safety or efficacy of the compound has been established to the satisfaction of any regulatory authority or that it will receive regulatory approval.
Multiple Myeloma Conversations Webinar on the Latest anti-BCMA Therapy Data from ASCO & EHA 2023
Learn more about recent BCMA-targeted monotherapy datasets presented at ASCO & EHA 2023, including DREAMM-3. This webinar/symposium was originally delivered on July 13, 2023, when BLENREP monotherapy was approved in the EU for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US and EU. The GSK compound discussed in this presentation is investigational. The information in this presentation is not intended to imply that clinical safety or efficacy of the compound has been established to the satisfaction of any regulatory authority or that it will receive regulatory approval.
Multiple Myeloma Conversations Webinar on Novel MOAs in Relapsed Refractory Multiple Myeloma
Learn about the clinical impact of re-treating with the same therapy class in RRMM, as well as, BCMA-targeting agents with novel MOAs as an alternative to re-treatment in RRMM. This webinar/symposium was originally delivered on September 14, 2022, when BLENREP monotherapy was approved in the US and EU for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US and EU. The GSK compound discussed in this presentation is investigational. The information in this presentation is not intended to imply that clinical safety or efficacy of the compound has been established to the satisfaction of any regulatory authority or that it will receive regulatory approval.
Controversies in Multiple Myeloma (COMy) 2022 Symposia on Unlocking the Potential of Novel BCMA combinations
Learn about the changing multiple myeloma therapeutic landscape, and the potential of novel BCMA combinations in multiple myeloma. This webinar/symposium was originally delivered on May 13, 2022, when BLENREP monotherapy was approved in the US and EU for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US and EU. The GSK compound discussed in this presentation is investigational. The information in this presentation is not intended to imply that clinical safety or efficacy of the compound has been established to the satisfaction of any regulatory authority or that it will receive regulatory approval.
European Hematology Association 2022 on Potential Novel Combination Treatment in Multiple Myeloma
Learn about the dynamic landscape in multiple myeloma, integration of BCMA-targeted agents in early relapsed refractory multiple myeloma, and optimizing the benefit-risk profile and feasibility of sequencing of BCMA-targeted agents. This webinar/symposium was originally delivered on June 9, 2022, when BLENREP monotherapy was approved in the US and EU for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US and EU. The GSK compound discussed in this presentation is investigational. The information in this presentation is not intended to imply that clinical safety or efficacy of the compound has been established to the satisfaction of any regulatory authority or that it will receive regulatory approval.
Multiple Myeloma Conversations Webinar on Understanding Real-World Evidence in Triple-Class Relapsed Refractory Multiple Myeloma
Learn about the changing multiple myeloma therapeutic landscape, the importance of real-world evidence, and emerging real-world datasets for agents recently approved for the treatment of triple-class exposed/refractory multiple myeloma. This webinar/symposium was originally delivered on April 20, 2022, when BLENREP monotherapy was approved in the US and EU for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US and EU. The GSK compound discussed in this presentation is investigational. The information in this presentation is not intended to imply that clinical safety or efficacy of the compound has been established to the satisfaction of any regulatory authority or that it will receive regulatory approval.
MOMENTUM: A Study of Momelotinib vs Danazol in Patients With Symptomatic and Anemic Myelofibrosis
Learn more about the phase 3 MOMENTUM study of momelotinib vs danazol in patients with symptomatic and anemic myelofibrosis, including the results at 24 weeks
International Myeloma Society (IMS) 2023 Symposium on the Management of the Aging Population in Multiple Myeloma
Learn more about the impact of aging population on the incidence and treatment of multiple myeloma. This webinar/symposium was originally delivered on November 30, 2021, when BLENREP monotherapy was approved in the EU for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US and EU. The GSK compound discussed in this presentation is investigational. The information in this presentation is not intended to imply that clinical safety or efficacy of the compound has been established to the satisfaction of any regulatory authority or that it will receive regulatory approval.
Individualised Strategies to Optimize First-Line Maintenance Therapy in Advanced Ovarian Cancer
Learn about recent progress in first-line maintenance therapy for Ovarian Cancer
ESGO 2023 Niraparib OC Symposium Recording
ESGO 2023 Niraparib OC Symposium Recording
ESMO 2022 Ovarian Cancer symposium
AVANT-GARDE: Reframing the art of first-line maintenance therapy to optimize long-term outcomes in advanced ovarian cancer
ESMO 2022 Dr Lorusso highlights interview
ESMO 2022 highlights: An interview with Dr. Domenica Lorusso
ESMO 2022 Dr Gourley Highlights Interview
ESMO 2022 highlights: An interview with Professor Charlie Gourley
ESGO 2022 Symposium
Conversations and Controversies in First-Line Maintenance Therapy for Advanced Ovarian Cancer
SE-GBL-ON-WCNT-200001 | November 2023